This article was originally published by Arun Kumar, Sandeep Kumar, and Arun Nanda in Adv Pharm Bull. 2018 Aug; 8(3): 355–363 under a Creative Commons License. Abstract Pharmaceutical Co-crystals are not new,…
The post A Review about Regulatory Status …
A Review about Regulatory Status and Recent Patents of Pharmaceutical Co-Crystals Read Post »
This paper was originally published by Emanuel Almeida Moreira de Oliveira and Karen Luise Lang in Journal of Applied Pharmaceutical Science Vol. 8(08), pp 157-165, August, 2018 under the terms of the…
The post Drug Repositioning: Concept, Classificati…
There is no simple way to explain drug prices, particularly in the US market, where drug prices vary considerably more than they do in other countries. Most Americans are familiar…
The post PBMs, Formularies, and Rebates: What Investors Should Know app…
PBMs, Formularies, and Rebates: What Investors Should Know Read Post »
This article was originally published by Gerard T. Vondeling, Qi Cao, Maarten J. Postma, and Mark H. Rozenbaum in Applied Health Economics and Health Policy (2018) pp.1-8 under a Creative Commons Attribution-NonCommercial…
The post The Impact of Patent…
The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review Read Post »
Former Congressman Henry Waxman was recently interviewed for the Clause 8 podcast about how he worked together with Sen. Orrin Hatch to pass the Hatch-Waxman Act and its aftermath. Congressman…
The post Clause 8 Podcast Interview with Co-Author of the…
Clause 8 Podcast Interview with Co-Author of the Hatch-Waxman Act Read Post »
This paper was originally published by Witold Jamróz, Joanna Szafraniec, Mateusz Kurek, and Renata Jachowicz in Pharmaceutical Research September 2018, 35:176 under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/li…
There are more than 7,000 diseases that are considered “rare,” that is, affecting fewer than 200,000 Americans. Yet around one in ten Americans lives with at least one of these…
The post Orphan Drug Patents: Concerns Raised by Payers and Policy Makers …
Orphan Drug Patents: Concerns Raised by Payers and Policy Makers Read Post »
A few years ago, there was much talk of the “patent cliff” facing blockbuster drugs like Lipitor and other huge name-brand drugs. The “patent cliff” may have spelled the end…
The post Why Generic Drug Makers May Benefit from 505(b)(2) Approval appeared…
Why Generic Drug Makers May Benefit from 505(b)(2) Approval Read Post »
This article was originally published by Li Du in BMC Medical Ethics 2018 19:29 under a creative commons license. Abstract Background The patenting of human genes has been the subject…
The post Patenting human genes: Chinese academic articles’ portraya…
Patenting human genes: Chinese academic articles’ portrayal of gene patents Read Post »
Drug development is one of the world’s most high-risk / high-reward industries, with the vast majority of drugs created never making it to market. Of those that do make it…
The post The 505(b)(2) Drug Patent Approval Process: Uses and Potential Advanta…
The 505(b)(2) Drug Patent Approval Process: Uses and Potential Advantages Read Post »